血清肿瘤标志物联合检测在肺癌诊断中的临床意义

摘要

Objective To investigate the clinical application value of joint detection for serum tumor markers, such as carcino embryonie antigen (CEA), cytokeratins 19 fragment (CYFRA21-1), neuron specific enolase (NSE), and squamous cell carcinoma antigen (SCCA) for diagnosis of lung cancer.Methods There were 68 patients with lung cancer as the lung cancer group, and another 65 healthy people as the control group. Microparticle chemiluminescence was applied for content detection of CEA, CYFRA21-1, NSE, and SCCA. Comparisons were made on sensitivity, specificity and accuracy between single and joint detection of tumor markers.Results The lung cancer group had much higher contents of CEA, CYFRA21-1, NSE, and SCCA than the control group (P<0.05). The joint detection of 4 tumor markers had sensitivity as 81% and accuracy as 86%, which were all higher than those of single detection. The difference had statistical significance (P<0.05). Conclusion Detection of serum CEA, CYFRA21-1, NSE, and SCCA has clinical application value in diagnosis of lung cancer. Joint detection can improve sensitivity and accuracy of diagnosis with good specificity and it is helpful for improving detection rate of lung cancer.%目的：探讨血清肿瘤标志物癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、鳞状细胞癌相关抗原(SCCA)联合检测在肺癌诊断中的临床应用价值。方法68例肺癌患者为肺癌组,65例健康体检者为对照组,采用微粒子化学发光法检测血清中CEA、CYFRA21-1、NSE、SCCA含量,并比较肿瘤标志物单独或联合检测肺癌的灵敏度、特异度和准确度。结果肺癌组血清CEA、CYFRA21-1、NSE、SCCA含量均明显高于对照组(P<0.05),4种肿瘤标志物联合检测的灵敏度为81%,准确度为86%,明显高于单独检测,差异具有统计学意义(P<0.05)。结论血清CEA、CYFRA21-1、NSE、SCCA检测在肺癌诊断中具有临床应用价值,联合检测可提高诊断的灵敏度和准确度,且具有较好的特异度,有助于提高肺癌的检出率。